Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsJames Revkin, MD, FACC, FACP, FCCP
Associate Clinical ProfessorDownloadHi-Res Photo
About
Copy Link
Titles
Attending Physician: Cardiology Fellows Clinic
Biography
Dr. Revkin specializes in the primary and secondary prevention of cardiovascular disease. He is also an expert in the design and conduct of clinical trials in cardiovascular and metabolic diseases
Last Updated on March 07, 2023.
Appointments
Cardiovascular Medicine
Associate Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Postdoctoral Trainee
- Center for Bioengineering University of Washington (1988)
- Fellow
- Yale University School of Medicine (1987)
- Resident
- Columbia-Presbyterian Medical Center, New York, NY (1984)
- MD
- Brown University (1981)
- BA
- Williams College, Philosophy/French (1976)
Research
Copy Link
Overview
My most current activities have been related to the design, conduct, and interpretation of data for large, industry sponsored, cardiovascular outcomes trials in the area of atherosclerosis, thrombosis, hypertension, heart failure, obesity, and diabetes. I am a subject matter expert in use of vascular imaging biomarkers to assess the clinical efficacy of pharmaceutical agents in slowing the progression of atherosclerosis.
ORCID
0009-0000-5383-9879
Research at a Glance
Yale Co-Authors
Frequent collaborators of James Revkin's published research.
Publications Timeline
A big-picture view of James Revkin's research output by year.
Forrester Lee, MD
Lawrence Young, MD
Michael Cleman, MD
36Publications
6,249Citations
Publications
2024
Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review
Javaheri A, Ozcan M, Moubarak L, Smoyer K, Rossulek M, Revkin J, Groarke J, Tarasenko L, Kosiborod M. Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review. Heliyon 2024, 10: e35916. PMID: 39229539, PMCID: PMC11369438, DOI: 10.1016/j.heliyon.2024.e35916.Peer-Reviewed Original ResearchCitationsConceptsGDF-15 concentrationsGrowth differentiation factor 15Differentiation factor 15GDF-15Heart failureMultivariate analysisRenal functionComposite outcomeAdverse outcomesOptimal treatment regimensPredictors of mortalityCardiovascular-related mortalityCross-sectional studyPrognostic roleTreatment regimensClinical risk prediction modelsPoor outcomeRisk prediction modelExercise capacityEligibility criteriaPatientsPRISMA guidelinesMortalityNonfatal outcomesOutcomesThe mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review
Dunne R, Crawford J, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L, Bonomi P. The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review. Journal Of Cachexia Sarcopenia And Muscle 2024, 15: 1628-1640. PMID: 39095951, PMCID: PMC11446707, DOI: 10.1002/jcsm.13510.Peer-Reviewed Original ResearchCitationsAltmetricConceptsWeight loss categoriesSystematic literature reviewPancreatic cancerColorectal cancerAssessment of weight changeStatistically significant poorer survivalLoss categoriesUnintentional weight lossRisk of cachexiaWeight lossPoor survivalInternational consensusAssociated with significantly poorer survivalMortality burdenLiterature reviewEligibility criteriaPRISMA guidelinesCancer-associated cachexiaColorectalProgressive functional impairmentClinical practiceFunctional impairmentWasting disordersPoor prognosisWeight changeMortality burden of pre‐treatment weight loss in patients with non‐small‐cell lung cancer: A systematic literature review and meta‐analysis
Bonomi P, Crawford J, Dunne R, Roeland E, Smoyer K, Siddiqui M, McRae T, Rossulek M, Revkin J, Tarasenko L. Mortality burden of pre‐treatment weight loss in patients with non‐small‐cell lung cancer: A systematic literature review and meta‐analysis. Journal Of Cachexia Sarcopenia And Muscle 2024, 15: 1226-1239. PMID: 38650388, PMCID: PMC11294038, DOI: 10.1002/jcsm.13477.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNon-small-cell lung cancerInternational consensus criteriaHazard ratioStatistical heterogeneityMeta-analysisWeight lossLung cancerSubgroup analysisPre-treatment weight lossAssociated with inferior survivalImpact of cachexiaKaplan-Meier curvesRandom-effects modelInferior survivalOverall survivalWorse survivalSurvival outcomesHigher mortality riskAdult patientsPoor prognosisClinical decision-makingClinical trialsMultivariate analysisCachexiaIndependent reviewers screened titlesPhase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design
Groarke J, Crawford J, Collins S, Lubaczewski S, Breen D, Harrington M, Jacobs I, Qiu R, Revkin J, Rossulek M, Saxena A. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design. Journal Of Cachexia Sarcopenia And Muscle 2024, 15: 1054-1061. PMID: 38500292, PMCID: PMC11154777, DOI: 10.1002/jcsm.13435.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPhysical activityPhysical functionPhase 2 studyCancer cachexiaGDF-15 concentrationsGDF-15Unintentional loss of weightLumbar skeletal muscle indexQuality of lifeSkeletal muscle indexBiomarker of cancer cachexiaNon-small-cell lungIncidence of adverse eventsResponse Evaluation CriteriaGrowth differentiation factor 15Safety laboratory testsOpen-label treatmentPlacebo-controlled studyCharacteristics of cachexiaCancer-related cachexiaMetabolic wasting syndromeHuman monoclonal antibodyCancer-relatedDifferentiation factor 15Phase 1 data
2023
A Phase 1b First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
Crawford J, Calle R, Collins S, Weng Y, Lubaczewski S, Buckeridge C, Wang E, Harrington M, Tarachandani A, Rossulek M, Revkin J. A Phase 1b First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia. Clinical Cancer Research 2023, 30: 489-497. PMID: 37982848, PMCID: PMC10831332, DOI: 10.1158/1078-0432.ccr-23-1631.Peer-Reviewed Original ResearchCitationsAltmetricThe mortality burden of cachexia in patients with non-small cell lung cancer: A meta-analysis.
Bonomi P, Crawford J, Dunne R, Roeland E, Smoyer K, Siddiqui M, McRae T, Rossulek M, Revkin J, Tarasenko L. The mortality burden of cachexia in patients with non-small cell lung cancer: A meta-analysis. Journal Of Clinical Oncology 2023, 41: e24075-e24075. DOI: 10.1200/jco.2023.41.16_suppl.e24075.Peer-Reviewed Original ResearchCitationsConceptsNon-small cell lung cancerInternational consensus criteriaCell lung cancerOverall survivalSubgroup analysisWeight lossLung cancerStatistical heterogeneityTreatment of NSCLCInferior overall survivalImpact of cachexiaRisk of mortalityFunnel plot analysisHigher mortality riskPrevious weight lossHigh statistical heterogeneitySystematic literature reviewRandom-effects modelBase-case analysisSubstantial publication biasMeta-analysis resultsPoor outcomeMortality burdenCachexiaMortality riskPhase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia.
Crawford J, Lubaczewski S, Tarachandani A, Harrington M, Weng Y, Qiu R, Collins S, Rossulek M, Revkin J. Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia. Journal Of Clinical Oncology 2023, 41: tps12147-tps12147. DOI: 10.1200/jco.2023.41.16_suppl.tps12147.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGDF-15 concentrationsCancer cachexiaPhysical activityBody weightSelective humanized monoclonal antibodyNon-small cell lungGrowth differentiation factor 15Double-blind periodMultifactorial metabolic syndromeSafety laboratory testsUnintended weight lossWeek 12 visitPlacebo-controlled studyOpen-label treatmentPhase 2 studyDifferentiation factor 15Humanized monoclonal antibodyE max modelSkeletal muscle massQuality of lifePrimary endpointSecondary endpointsWeek 72Adverse eventsGDF-15The mortality burden of cachexia in patients with colorectal or pancreatic cancer: A systematic literature review.
Dunne R, Bonomi P, Crawford J, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L. The mortality burden of cachexia in patients with colorectal or pancreatic cancer: A systematic literature review. Journal Of Clinical Oncology 2023, 41: 87-87. DOI: 10.1200/jco.2023.41.4_suppl.87.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPancreatic cancerPoor survivalInternational Consensus Diagnostic CriteriaRisk of cachexiaUnintentional weight lossCancer-associated cachexiaSystematic literature reviewConsensus diagnostic criteriaProgressive functional impairmentPoor prognosisColorectal cancerUnivariate analysisMortality burdenFunctional impairmentCachexiaPRISMA guidelinesDiagnostic criteriaEligibility criteriaPatientsClinical practiceRoutine assessmentMultivariate analysisSignificant associationWasting disorderCancer
2022
1616P The mortality burden of cachexia in patients with non-small cell lung cancer: A systematic literature review
Bonomi P, Crawford J, Dunne R, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L. 1616P The mortality burden of cachexia in patients with non-small cell lung cancer: A systematic literature review. Annals Of Oncology 2022, 33: s1281. DOI: 10.1016/j.annonc.2022.07.1919.Peer-Reviewed Original Research1263O Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy
Roeland E, Fintelmann F, Yang R, Tarasenko L, McRae T, Revkin J, Bonomi P. 1263O Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy. Annals Of Oncology 2022, 33: s1125. DOI: 10.1016/j.annonc.2022.07.1396.Peer-Reviewed Original Research
Get In Touch
Copy Link